X4 Pharmaceuticals News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from X4 pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In X4 Pharmaceuticals Today - Breaking & Trending Today

X4 Pharmaceuticals (NASDAQ:XFOR) Price Target Increased to $5.00 by Analysts at HC Wainwright

X4 Pharmaceuticals (NASDAQ:XFOR – Get Free Report) had its target price lifted by equities researchers at HC Wainwright from $3.00 to $5.00 in a research note issued on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 352.49% from the company’s […] ....

Paula Ragan , Adams Mostafa , Securities Exchange Commission , Pharmaceuticals Stock Performance , Capital Partners , Pharmaceuticals Company Profile , Pharmaceuticals Daily , Stonepine Capital Management , Pharmaceuticals Inc , Bain Capital Life Sciences Investors , Sg Americas Securities , Get Free Report , Exchange Commission , Capital Life Sciences Investors , Capital Management , X4 Pharmaceuticals , Nasdaq Xfor , Boost Price Target , Hc Wainwright ,

Brookline Capital Management Equities Analysts Increase Earnings Estimates for X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Free Report) – Equities research analysts at Brookline Capital Management increased their FY2026 earnings estimates for X4 Pharmaceuticals in a research report issued to clients and investors on Monday, April 29th. Brookline Capital Management analyst L. Cann now expects that the company will earn $0.32 per share for the year, […] ....

Adams Mostafa , Barclays Plc , Sg Americas Securities , Securities Exchange Commission , Pharmaceuticals Stock , Pharmaceuticals Inc , Pharmaceuticals Daily , Capital Partners , Stonepine Capital Management , Free Report , Brookline Capital Management , Capital Management , Get Free Report , Exchange Commission , X4 Pharmaceuticals , Nasdaq Xfor , Earnings Estimates ,

US FDA approves X4 Pharmaceuticals' drug for immunodeficiency disease

(Reuters) -X4 Pharmaceuticals said on Monday the U.S. FDA has approved its therapy to treat a rare genetic immunodeficiency disease in patients 12 years of age and older, sending its shares up 16% before the bell. X4's mavorixafor, which will be sold under the brand name Xolremdi, is the first therapy to get U.S. approval specifically for the treatment of WHIM syndrome. WHIM is characterized by disorders in which the body's immune system does not function properly. ....

Shinjini Ganguli , Christy Santhosh , Whim Syndrome , X4 Pharmaceuticals , S Fda , White Blood Cells , Immunodeficiency Disease , White Blood Cell Count , Immune System , Antibody Levels ,

X4 Pharmaceuticals (NASDAQ:XFOR) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of X4 Pharmaceuticals (NASDAQ:XFOR – Free Report) in a research note released on Friday, Benzinga reports. The brokerage currently has a $3.00 price objective on the stock. Separately, B. Riley lowered X4 Pharmaceuticals from a buy rating to a neutral rating and lowered their target price for […] ....

Paula Ragan , Adams Mostafa , Blackrock Inc , Stonepine Capital Management , Pharmaceuticals Stock Performance , Bain Capital Life Sciences Investors , Securities Exchange Commission , Pharmaceuticals Daily , Pharmaceuticals Company Profile , Pharmaceuticals Inc , Perceptive Advisors , Polar Capital Holdings Plc , Free Report , Exchange Commission , Capital Holdings Plc , Capital Management , Capital Life Sciences Investors , Get Free Report , X4 Pharmaceuticals , Nasdaq Xfor , Reiterated Rating , Hc Wainwright ,

Insider Selling: X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CEO Sells 199,531 Shares of Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR – Get Free Report) CEO Paula Ragan sold 199,531 shares of the company’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $0.73, for a total transaction of $145,657.63. Following the completion of the transaction, the chief executive officer now owns 876,347 shares […] ....

Paula Ragan , Blackrock Inc , Polar Capital Holdings Plc , Pharmaceuticals Inc , Bain Capital Life Sciences Investors , Stonepine Capital Management , Pharmaceuticals Daily , Perceptive Advisors , Pharmaceuticals Price Performance , Get Free Report , Capital Holdings Plc , Capital Management , Capital Life Sciences Investors , X4 Pharmaceuticals , Nasdaq Xfor , Insider Trading , Nsider Trades ,